DALLAS, Dec. 8, 2009 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring La Jolla Pharmaceuticals Co. (Nasdaq:LJPC). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
It is available at: http://www.investorsoup.com/lp/LJPC
Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup
La Jolla Pharmaceutical Co. (LJPC) is a biopharmaceutical company focused on the development and testing of Riquent as a treatment for lupus nephritis, an antibody-mediated disease caused by abnormal B cell production of antibodies that attack healthy tissues. The Company's wholly owned subsidiary is La Jolla Ltd.
Message Board Search for LJPC: http://www.boardcentral.com/boards/LJPC
In the report, the analyst notes:
"In late November, LJPC announced that its Special Meeting of Stockholders, which was originally convened on October 30, 2009, and subsequently adjourned twice, was adjourned for a third time on November 24, 2009, and has not been scheduled to be reconvened. As described in the Proxy Statement distributed to stockholders on or about October 7, 2009, the stockholders of the Company were being asked to vote upon a proposal to approve the liquidation and dissolution of the Company pursuant to a plan of liquidation and dissolution.
"Approximately 92% of the Company's stockholders failed to return their proxy cards or otherwise indicate their votes with respect to this proposal prior to the start of the stockholders' meeting. To pass, this proposal required the approval by holders of at least a majority of the Company's outstanding voting shares."
To read the entire report visit: http://www.investorsoup.com/lp/LJPC
See what investors say about these stocks at: http://www.stockhideout.com/
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit http://www.InvestorSoup.com
InvestorSoup.com Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.